Simmitinib not checked
Shanghai Runshi Pharmaceutical Technology Co., Ltd · SOMCL-15-290
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)”In the company’s words, NCT06577376 on ClinicalTrials.gov
- Tested for
- Advanced Oesophageal Squamous Cell Carcinoma, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past, Advanced Solid Tumor
- Main trialPhase 3
- “To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.”In the company’s words, NCT06656091 on ClinicalTrials.gov
- Other names
- SOMCL-15-290
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- 30 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Jan 2027 | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | |
| Phase 1/2Not yet recruiting | 26 Aug 2026 | A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | |
| Phase 1/2Not yet recruiting | 30 Jan 2027 | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | |
| Phase 2Unknown | 30 Jan 2026 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | |
| Phase 1Unknown | 31 Jan 2023 | A Phase I Trial of Simmitinib in Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026